- Home
- NVCT vs SLS Comparison
NVCT vs SLS Comparison
Compare NVCT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCT
- SLS
- Stock Information
- Founded
- NVCT 2020
- SLS 2012
- Country
- NVCT United States
- SLS United States
- Employees
- NVCT N/A
- SLS N/A
- Industry
- NVCT Medicinal Chemicals and Botanical Products
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- NVCT Health Care
- SLS Health Care
- Exchange
- NVCT Nasdaq
- SLS Nasdaq
- Market Cap
- NVCT 184.9M
- SLS 169.6M
- IPO Year
- NVCT 2022
- SLS N/A
- Fundamental
- Price
- NVCT $7.26
- SLS $2.05
- Analyst Decision
- NVCT Strong Buy
- SLS
- Analyst Count
- NVCT 3
- SLS 0
- Target Price
- NVCT $17.00
- SLS N/A
- AVG Volume (30 Days)
- NVCT 186.4K
- SLS 3.3M
- Earning Date
- NVCT 08-05-2025
- SLS 08-12-2025
- Dividend Yield
- NVCT N/A
- SLS N/A
- EPS Growth
- NVCT N/A
- SLS N/A
- EPS
- NVCT N/A
- SLS N/A
- Revenue
- NVCT N/A
- SLS N/A
- Revenue This Year
- NVCT N/A
- SLS N/A
- Revenue Next Year
- NVCT N/A
- SLS N/A
- P/E Ratio
- NVCT N/A
- SLS N/A
- Revenue Growth
- NVCT N/A
- SLS N/A
- 52 Week Low
- NVCT $4.44
- SLS $0.77
- 52 Week High
- NVCT $11.80
- SLS $2.22
- Technical
- Relative Strength Index (RSI)
- NVCT 29.72
- SLS 64.79
- Support Level
- NVCT $7.84
- SLS $1.50
- Resistance Level
- NVCT $8.27
- SLS $2.22
- Average True Range (ATR)
- NVCT 0.45
- SLS 0.15
- MACD
- NVCT -0.08
- SLS 0.05
- Stochastic Oscillator
- NVCT 6.12
- SLS 81.81
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.